In the final week of 2025, key stocks including Micron, Nike, Oracle, Rivian, and Amicus Therapeutics dominated investor attention with notable earnings reports and corporate developments. Micron’s exceptional first-quarter results lifted shares to record levels, while Nike suffered a steep sell-off due to weakening China demand and increased U.S. tariffs. Oracle’s stock surged on the TikTok U.S. deal news, offsetting earlier concerns over a stalled Michigan data center project. Meanwhile, Rivian experienced a sharp rally triggered by positive analyst upgrades linked to its upcoming R2 vehicle launch. Amicus Therapeutics also posted a significant gain after BioMarin Pharmaceutical announced a definitive acquisition deal valued at approximately $4.8 billion.

Micron and Nike: Diverging Earnings and Market Reactions

Micron Technology delivered a remarkable earnings surprise on Thursday, posting record first-quarter revenue, profit, and margins. This performance was driven by surging memory prices and strong demand from artificial intelligence workloads. Shares gained over 10% on Thursday and added nearly 7% on Friday, closing the week at new all-time highs. Morgan Stanley analyst Joseph Moore hailed Micron’s upside as one of the largest in U.S. semiconductor history and emphasized ongoing supply-demand imbalances fueled by AI growth.

In sharp contrast, Nike’s stock plunged more than 10% on Friday after the company reported quarterly earnings that beat estimates but revealed deteriorating sales in China and rising input costs in the U.S. due to increased tariffs. The stock closed the week down over 13%. Truist analyst Joseph Civello highlighted that weaker-than-expected performance in China and the Converse brand pressured Nike’s third-quarter outlook. Nevertheless, Civello expressed cautious optimism about Nike’s product improvements and expansion efforts with retail partners, suggesting a potential gradual recovery ahead.

Oracle, Rivian, and Amicus Therapeutics: Corporate Catalysts in Focus

Oracle experienced mixed performance throughout the week. Early selling pressure related to uncertainty over a planned $10 billion Michigan data center eased after the company clarified that final equity negotiations remain on schedule despite Blue Owl Capital’s withdrawal from the project. Oracle’s stock rebounded with an 8% gain on Friday when news emerged that ByteDance agreed to sell over 80% of TikTok’s U.S. operations to a consortium including Oracle, Silver Lake, and Abu Dhabi-based MGX.

Rivian shares surged more than 33% in Thursday and Friday trading following an upgrade from Baird, which lifted the price target to $25 from $14 and rated the company Outperform. Analyst Ben Kallo cited Rivian’s recent autonomy and AI day event, which showcased custom chips and detailed autonomous driving strategies. The upcoming launch of the 2026 R2 electric vehicle is expected to bolster brand strength and boost deliveries starting mid-2026.

Amicus Therapeutics rallied over 30% on Friday after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at approximately $4.8 billion. BioMarin’s CEO, Alexander Hardy, emphasized the strategic fit combining BioMarin’s global commercial scale and manufacturing capabilities with Amicus’s portfolio. The acquisition is anticipated to close by the second quarter of 2026.

Stocks: Market Outlook

As 2025 winds down, Micron’s strong earnings forecast reflects robust AI-driven demand sustaining semiconductor momentum. Meanwhile, Nike’s challenges in China and rising U.S. tariffs underscore ongoing geopolitical pressures impacting consumer goods. Oracle’s rebound amid the TikTok deal highlights regulatory and strategic shifts in the tech sector. Rivian’s optimistic upgrade positions it for growth with the 2026 R2 launch, while Amicus’s acquisition by BioMarin signals consolidation trends in biotechnology. Investors will likely monitor these developments closely as they set the tone for equities in early 2026.